A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug Avastin.
Pfizer's cut-price version of Avastin wins EU panel greenlight
![Pfizer's cut-price version of Avastin wins EU panel greenlight]()
Reviewed by jenisht
on
December 15, 2018
Rating:
No comments: